The global liquid biopsy market is expected to reach $4,380.534 million by 2024 from $1,246.248 million in 2018 growing at a CAGR of 23.31%. Liquid biopsy, also known as fluid biopsy is a non-invasive technique that enables the discovery of a range of information about a tumor through sampling and analysis of non-solid biological tissue such as blood. The evolution of sensitive technologies has enabled the development of liquid biopsies for various clinical applications including screening for the presence of disease, monitoring treatment response, patient stratification, and therapy selection, and detection of recurrence or the presence of residual disease after surgery. The growth in the market may be attributed to the rising patient population base owing to the rising prevalence of cancer. Rising preference for non-invasive procedures will also augment the growth of the liquid biopsy market during the given forecast period. However unclear regulatory scenarios pertaining to liquid biopsy along with unfavorable reimbursement policies might restrain the growth of the market during the given time frame.
This research study examines the current market trends related to demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases, and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top-down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global liquid biopsy market value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the global liquid biopsy market.
Major industry players profiled as part of the report are F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Genomic Health
| Report Metric | Details |
| Market size value in 2018 | US$1,246.248 million |
| Market size value in 2024 | US$4,380.534 million |
| Growth Rate | CAGR of 23.31% from 2018 to 2024 |
| Base year | 2018 |
| Forecast period | 2019–2024 |
| Forecast Unit (Value) | USD Million |
| Segments covered | Sample Tissue, Biomarkers, Application, And Geography |
| Regions covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies covered | F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Genomic Health, QIAGEN, NeoGenomics Laboratories, Inc., OncoCyte Corporation, Biocept, Inc., LungLife AI, Inc. |
| Customization scope | Free report customization with purchase |
Segmentation
Frequently Asked Questions (FAQs)
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.
